We’re very happy to bring you Part 4 that will wrap up the Special Episode podcast of Dialogues on AI Digital Pathology! In this Part 4 podcast, our guests – KOL Hepatologists and Pharma Thought Leaders in NASH – continue their discussions in response to questions by Pharma companies and clinical investigators. Find out their views on how AI Digital Pathology (AI-DP) can effectively impact NASH drug development, preclinical studies and clinical practice with granular histopathological data.  Please click here to view the Key Takeaways for Part 4 or go to https://tinyurl.com/b4ttvb4s. Our ..read more

Dialogues on AI Digital Pathology is releasing Part 4 of its Special Episode real soon! Listen to this trailer for a snippet of Part 4 with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they continue their discussions on AI Digital Pathology (AI-DP), and the application and future of AI-DP in clinical practice, liver research, and drug development.  Guests Prof. Stephen Harrison, Medical Director, Pinnacle Clinical Research Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne University and Pitié-Salpêtrière Hospital Dr. Judith Ertle, Senior Clinical Program Lead N ..read more

Guests Prof. Stephen Harrison (Pinnacle Clinical Research) Prof. Vlad Ratziu (Sorbonne University Pitié-Salpêtrière Hospital) Dr. Judith Ertle (Boehringer Ingelheim) Dr. Karin Conde-Knape (Novo Nordisk) Ms. Kitty Yale (Akero Therapeutics) Moderator  Dr. Nikolai Naoumov (Novartis) Key Takeaways 1) The innovation and qualities that AI Digital Pathology (AI-DP) brings to drug development can be described as a disruptive technology as it expands the knowledge of NASH pathobiology, introduces standardization and reproducibility on a fully quantitative scale, allows to better define a dose-re ..read more

Our Special Episode conversation on AI Digital Pathology in NASH Drug Development continues (in Parts 3 and 4) with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they respond to questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can augment clinical trial data and work alongside pathologists to detect granular information that could be pivotal for determining patient recruitment, staging and treatment responses. The full Part 3 podcast will be launched early next week, so click here to listen to the Trailer of ..read more

Our guest KOL liver pathologists continue their conversation from Part 1 following the FDA Webcast, by responding to more questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can aid pathologists with precise assessment to better interpret the disease biology of NASH.  We’d like to thank our Guests and Moderator for their kind participation and professional views! Prof. Pierre Bedossa Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France Prof. Zachary Goodman Director of Hepatic Pathology Consu ..read more

Here's the Official Trailer for Part 2 of our Special Episode of Dialogues on AI Digital Pathology, which is coming up in a week! Listen to these sound bites from our guest KOL liver pathologists, Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov about AI digital pathology as a complementary tool for pathologists in interpreting the disease biology of NASH. This is a continuation from Part 1, where the KOLs commented on the key takeaways from the recent FDA webcast on NASH Drug Development, and questions from the ..read more

We’re very excited to bring you a Two-Part Special Episode of Dialogues on AI Digital Pathology!  Listen to our guests, KOL liver pathologists as they discuss the recent FDA Webcast on NASH drug development and utilization of AI digital pathology as potential clinical trial endpoints. Here’s Part 1, where the KOL liver pathologists will discuss key takeaways from the recent FDA Webcast on NASH Drug Development, and respond to questions sent in by Pharma companies and clinical investigators on potential clinical trial strategies using AI digital pathology following the Webcast.  Gues ..read more

We're commencing a two-part Special Episode of Dialogues on AI Digital Pathology! This episode brings together our guests, Key Opinion Leaders in liver pathology, who will be speaking about the key takeaways from the recent FDA webcast on NASH Drug Development, and responding to questions from the industry on designing clinical trial strategies with AI digital pathology. Here's a Trailer of Part 1 with snippets from Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov. Guests Prof. Pierre Bedossa Professor of Patho ..read more

In the upcoming episode 4 of Dialogues on AI Digital Pathology, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis). Nikolai is a physician-scientist with a professional career combining academic research, clinical care and drug development – all focused on liver diseases. With his current work focusing on digital pathology with AI assessment of liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai shares his views about the advantages and impact of AI digital pathology in ..read more

Episode 3 of Dialogues on AI Digital Pathology is coming up soon! Here's a sound bite from our guest, Dr. Suneil Hosmane, Executive Vice President and Global Head of Diagnostics at GENFIT, who will share his views on how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts and benefit patient outcomes. Watch out for our updates next week when Episode 3 goes Live!  ..read more